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Background: Chagas disease has spread beyond 
its original borders on the American continent with 
migration. It can be transmitted from mother to 
child, through organ transplantation and transfu-
sion of blood and blood products. It is necessary to 
determine when to screen for this infection. Aim: 
Our objective was to evaluate the appropriateness 
of screening for  Trypanosoma cruzi  infection in Latin 
American migrants and their descendants. Methods: 
We reviewed the literature using rigorous criteria. 
The quality of evidence was ranked according to the 
GRADE classification. An evidence to decision frame-
work was adopted to provide information on the most 
relevant aspects necessary to formulate recommen-
dations. Results: The 33 studies evaluated revealed a 
prevalence of T. cruzi  infection among Latin American 
migrants in Europe of 6.08% (95% confidence inter-
val (CI): 3.24–9.69; 28 studies). Vertical transmission 
occurred in three of 100 live births (95% CI: 1–6; 13 
studies). The prevalence of cardiovascular disease was 
19% (95% CI: 13–27; nine studies), including only 1% 
severe cardiac events (95% CI: 0–2; 11 studies). The 
overall quality of evidence was low because of risk of 
bias in the studies and considerable heterogeneity of 
the evaluated populations. The recommendations took 
into account economic studies on the value of screen-
ing strategies and studies on acceptability of screen-
ing and knowledge of the disease in the affected 
population. Conclusions: We identified five situations 
in which screening for  T. cruzi  infection is indicated. 
We recommend screening persons from endemic areas 
and children of mothers from these areas.
Introduction
Chagas disease is endemic in 21 countries in Latin 
America and is present from the south of the United 
States (US) to the north of Argentina and Chile. 
Transmission in these countries is mainly vectorial, 
although migration to cities, vertical transmission and 
blood donations have enabled it to extend from rural to 
urban areas. Estimations from the year 2010 show that 
5,742,167 persons are infected with Trypanosoma cruzi. 
Of these, 62.4% live in the Southern Cone, with an 
at-risk population of 70.2 million people, 38,593 new 
cases per year (8,668 congenital cases) and 12,000 
related deaths per year. Furthermore, Chagas disease 
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continues to be the leading cause of cardiomyopathy 
in Latin America and is, according to the World Health 
Organization (WHO), a ‘forgotten’ or ‘neglected’ dis-
ease [1,2].
In Europe, Chagas disease is not monitored systemati-
cally, although available data suggest that prevalence 
rates are high in some countries. The highest numbers 
of cases in Europe are found, in order of prevalence, 
in Spain, Italy, the Netherlands, the United Kingdom, 
Germany and France [3]. According to one study, 
4,290 cases of Chagas disease were registered among 
Latin American immigrants in nine European coun-
tries in 2009, with a prevalence of 1.3 cases per 1,000 
migrants from endemic countries. In addition to poten-
tial underdiagnosis, prevalence among undocumented 
immigrants could be higher [4].
Spain is home to the largest number of infected per-
sons from Latin America and has the highest num-
ber of confirmed cases of Chagas disease in Europe 
(75% of the total). Prevalence differs for each group 
of immigrants by country and specific region of origin. 
Depending on the type of study and population ana-
lysed, the highest prevalence rates are found among 
immigrants from Bolivia (10–40%). Rates are lower 
in blood donors and pregnant women and higher in 
patients at reference centres where Chagas disease is 
screened for [5-9]. Some 53,000 potential carriers were 
thought to be living in Spain in 2009, and the rate of 
potentially infected blood donations ranged from 0.02 
to 2.35 per 1,000 inhabitants, with wide variations 
between Autonomous Communities [10]. According to a 
more recent study and data from the 2011 census and 
after applying values reported by Basile et al. [4], there 
are 68,636 T. cruzi–infected Latin American immigrants 
in Spain, of whom 22,100 are women of reproductive 
age [11].
In endemic areas,  T. cruzi  is vector-borne (reduviid 
bug). It can also be transmitted vertically, through 
blood and organ donation and, more rarely, oral con-
tact. Migration has led the disease to spread beyond 
its original borders, so that it can now be transmit-
ted from mother to child in non-endemic countries or 
if blood donations and transplants are not monitored 
[2,12].
Chagas disease has an acute phase, which, if left 
untreated, progresses to a chronic phase during which 
patients can develop cardiac, digestive or neurologi-
cal involvement. This occurs in 30–40% of infected 
persons 10–30 years after the acute phase and is a 
major cause of morbidity and mortality. Treatment with 
antiparasitic agents is effective in the acute phase, in 
reactivations in immunosuppressed patients, in the 
chronic phase (especially before the age of 18 years) 
and in the prevention of vertical transmission [2,12-
14]. Although, during the late chronic phase, tryp-
anocidal treatment can be indicated in adult patients 
with chronic  T. cruzi  infection and no specific organic 
damage [13], its effectiveness is highly questionable in 
cases of visceral involvement [2,12-14].
Given that Spain is a country with a high prevalence 
of T. cruzi infection and because early detection of this 
disease is advantageous (better response to treatment, 
prevention of materno-fetal transmission and of late 
organ complications), the Spanish Society of Infectious 
Diseases and Clinical Microbiology (Sociedad Española 
de Enfermedades Infecciosas y Microbiología Clínica; 
SEIMC) decided to draft guidelines on screening for 
this parasitosis in immigrants and refugees. Here, we 
present the methodology, results and recommenda-
tions of this initiative.
Methods
We performed a systematic review of the literature to 
determine whether screening had an impact on a series 
of relevant outcomes of interest for decision making. 
We then developed a working framework to formulate 
explicit, reasoned recommendations.
Review of the scientific literature
The Panel, which comprised the authors of the study, 
reviewed the scientific literature according to a protocol 
following methodological guidelines from the Cochrane 
Collaboration [15] and reported its findings according 
to the Preferred Reporting Items for Systematic Reviews 
and Meta-Analyses (PRISMA) statement [16].
Figure 1
Systematic review about screening of migrants for 
Trypanosoma cruzi, study eligibility, Prisma flow diagram
470 records 
identified through 
database searching
24 records suggested 
by panel members
494 records screened 
by title and abstract
429 records excluded
32 articles excludeda
65 full-text articles 
assessed for eligibility
33 studies included in 
the evidence synthesis
a Reason for exclusion of full-text articles: 12 narrative review 
articles; nine conference abstracts; four studies in endemic 
settings; two cost studies; two duplicates; one case report; one 
study in a non-eligible setting; one registry report.
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Clinical question
In order to draw up the recommendations, the Panel 
asked the following clinical question: Should immi-
grants and refugees be screened for T. cruzi infection?
In order to answer the question, the Panel identified 
the following outcomes of interest: (i) frequency of 
vertical transmission, transmission by blood/blood 
product transfusion and transmission by transplant, 
(ii) mild to moderate organ involvement (defined as 
the presence of heart failure or left ventricular ejection 
fraction < 50%, electrocardiogram abnormalities or dys-
phagia/constipation), (iii) severe organ involvement 
(defined as hospitalisation because of heart failure, 
need for a pacemaker or diagnosis of megasyndrome), 
(iv) T. cruzi  infection, (v) indications for a trypanocidal 
drug, (vi) mortality, (vii) organ involvement of any type 
after diagnosis and (viii) quality of life.
Inclusion criteria
Given the lack of clinical trials that compare the impact 
of screening for T. cruzi infection with not screening for 
it, we considered descriptive studies on screening in 
which a denominator could be established for the ref-
erence population. If this was not possible, we consid-
ered case series that described the clinical condition 
of patients with the disease. The population of inter-
est comprised immigrants or refugees older than 14 
years from endemic areas, except in the case of neo-
natal screening where we also took into consideration 
minors born to mothers at risk of vertical transmission. 
We took into account studies that reported experience 
of screening for  T. cruzi  in non-endemic countries in 
Europe. The studies had to provide clear detail, namely, 
test used and setting in which it was performed. By def-
inition, the test is performed in asymptomatic patients.
Literature search
A search strategy was designed to obtain relevant 
studies from MEDLINE (accessed via PubMed) and 
Table 1
Summary of outcomes of interest, systematic review about screening of migrants for Trypanosoma cruzi
Outcome Number of studies Quality of evidence Impact
Patients with T. cruzi infection
26 observational studies 
 
[5-7,9,22-43]
Low
1. Total pooled prevalence: 6% (95% CI: 
3–10); 
 
2. Among immigrants in general: 13% (95% 
CI: 7–21; I2 =  98.15%) 
 
3. Pregnant women: 4% (95% CI: 2–7; 
I2 = 96.28%) 
 
4. Blood donors: 0.42% (95% CI: 0.03–
1.08%; I2 = 82.06)
Vertical transmission of T. 
cruzi infection
13 observational studies 
 
[6,35-43,46,49,50]
Low
1. Pooled transmission rate: 3 per 100 live 
births (95% CI: 1–6; I2 = 21.40%) 
 
2. Symptoms of infection in 20% (95% CI: 
0–53; I2 = 32.4%)
Mild to moderate organ 
involvement: cardiovascular 
symptoms
9 observational studies 
 
[6,7,9,24,29,45-48]
Low Cardiovascular disease: 19% (95% CI: 13–27%; I2 = 88.36%)
Mild to moderate organ 
involvement: digestive 
symptoms
9 observational studies 
 
[7,24,25,28,29,45-48]
Low Gastrointestinal abnormalities: 5% (95% CI: 2–11; I2 = 89.62%)
Severe organ involvement
11 observational studies 
 
[6,7,9,24,25,28,29,45-48]
Low
1. Severe cardiac events: 1% (95% CI: 0–2; 
I2 = 57.9%) 
 
2. Severe gastrointestinal involvement 
(megasyndrome): 0% (95% CI: 0–1; 
I2 = 41.26%)
Indication for treatment
11 observational studies 
 
[6,29,30,35,37,39,43,45-48]
Very low
1. Initiation of trypanocidal therapy: 81% 
(95% CI: 67–93; I2 = 93.25%) 
 
2. End of treatment: 78% (95% CI: 65–89; 
I2 = 88.5%) 
 
3. Treatment-related adverse effects: 47% 
(95% CI: 32–63; I2 = 90.45%)
Mortality
2 observational studies 
 
[6,7]
Low Two reports of sudden cardiac death secondary to Chagas disease
CI: confidence interval.
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EMBASE (accessed via Ovid) up to October 2018. The 
strategy combined text words and controlled vocabu-
lary from sources related to screening and T. cruzi, with 
no major limits for year of publication, language or 
country (Supplement 1). The results of the search were 
recorded in an EndNoteX2 database to coordinate the 
eligibility and availability of the studies. The results of 
the search were complemented with additional refer-
ences provided by the Panel and based on references 
from the key studies. The investigators of the original 
studies were not contacted.
Data extraction
The Panel retrieved a series of descriptive character-
istics from each included study and recorded them on 
a predefined data extraction form. In addition to the 
objective and study design, we defined the context, 
number of participants and their origin, the test used 
to determine the disease, the criteria for positivity and 
all relevant specific information from any subgroup 
of interest (e.g. pregnant women). We also obtained 
numerical data that made it possible to calculate the 
prevalence or cumulative rate for each of the outcomes 
of interest, with their respective confidence intervals 
(CI) when available.
Risk of bias
Bias affecting the observational (cross-sectional) stud-
ies included was evaluated based on 10 items which 
assessed the internal and external validity of the stud-
ies [17]. The resulting classification defined the overall 
risk of bias as low, moderate or high. The information 
obtained from the evaluation of risk of bias was incor-
porated in the process applied to classify the quality 
of evidence.
Data analysis and evidence synthesis
We performed a narrative synthesis of results for 
each predefined outcome. When prevalence data were 
available, we calculated pooled estimates with their 
Figure 2
Prevalence of Trypanosoma cruzi infection: pooled analysis from studies included in the review
Heterogeneity between groups: p = 0.000
Overall  (I2 = 98.82%, p = 0.00);
BLOOD DONORS
Gabrielli 2013 [34]
Ortí Lucas 2009 [41]
Muñoz 2009 [7]
Lescure 2009 [26]
El Ghouzzi 2010 [33]
Subtotal  (I2 = 98.15%, p = 0.00)
Muñoz-Vilches 2012 [40]
Ramos 2012 [44]
Pirón 2008 [5]
PREGNANT WOMEN
Subtotal  (I2 = 96.28%, p = 0.00)
Cancino 2015 [32]
Frank 1997 [24]
Paricio-Talayero 2008 [43]
Angheben 2011 [23]
Martínez 2009 [38]
Angheben 2011 [23]
Roca 2011 [9]
Ramos 2012 [29]
Study
Perez-Ayala 2010 [6]
Angheben 2011 [23]
Soriano 2009 [31]
Avila Arzanegui 2013 [36]
Barona-Vilar 2012 [37]
O’Brien 2013 [35]
Perez-Molina 2011 [28]
Otero 2012 [42]
Muñoz 2009 [39]
Jackson 2010 [25]
Subtotal  (I2 = 82.06%, p = 0.00)
Rodríguez-Guardado 2009 [30]
Navarro 2011 [27]
IMMIGRANTS
6.08 (3.24, 9.69)
0.98 (0.17, 5.35)
9.69 (7.11, 13.07)
41.31 (37.03, 45.72)
23.62 (18.82, 29.21)
0.31 (0.11, 0.90)
13.30 (7.30, 20.71)
1.53 (0.60, 3.87)
1.28 (0.62, 2.63)
0.66 (0.36, 1.20)
3.93 (1.71, 6.98)
1.92 (1.28, 2.86)
2.02 (0.56, 7.07)
4.71 (3.30, 6.68)
0.00 (0.00, 12.06)
0.00 (0.00, 1.24)
11.28 (8.02, 15.64)
2.87 (1.90, 4.31)
6.47 (3.82, 10.75)
ES (95% CI)
31.15 (28.54, 33.89)
1.40 (0.48, 4.04)
4.31 (1.85, 9.69)
12.18 (7.94, 18.24)
11.62 (10.27, 13.12)
0.30 (0.17, 0.54)
11.00 (9.32, 12.95)
3.48 (2.31, 5.21)
3.41 (2.56, 4.51)
12.85 (10.92, 15.05)
0.42 (0.03, 1.08)
16.07 (8.69, 27.81)
15.94 (12.10, 20.72)
100.00
3.43
3.62
3.64
3.59
3.67
42.76
3.59
3.65
3.68
36.21
3.67
3.42
3.65
2.88
3.60
3.59
3.66
3.56
Weight
3.67
3.57
3.46
3.52
3.68
3.69
3.67
3.65
3.68
3.67
21.03
3.24
3.59
%
Prevalence estimate (95% CI)
  
0 10 20 30 40 50
Rate per 100 persons screened
CI: confidence interval.
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Clinical question
• Should immigrants and refugees undergo screening for T. cruzi infection?
Population of interest
• Migrants and refugees
Intervention
• Screening for T. cruzi infection
Comparison
• Not screening
Outcomes of interest
• Cases of vertical transmission resulting from transfusion or transplant
• Mild to moderate organ involvement (heart failure or LVEF < 50%, ECG abnormalities or dysphagia/constipation)
• Severe organ involvement (hospitalisation due to heart failure, need for a pacemaker or diagnosis of megasyndrome)
• Infection
• Indication for trypanocidal treatment
• Mortality
• Organ involvement of any type after diagnosis
• Quality of life
Is the problem a priority? Yes
Research evidence and remarks from the Panel
• High prevalence of immigrants from Latin America, especially Bolivia.
• Between 50,000 and 70,000 persons in Spain are thought to have the disease.
• Autochthonous transmission occurs in Spain, mainly by vertical transmission.
• Early detection in children of infected mothers indicates a very high rate of cure.
• Early detection improves response to treatment. Antiparasitic treatment is more effective in children and adolescents than in 
adults. It also makes it possible to identify women of reproductive age who have not yet had children (or who have had children 
and may wish to have more) and in whom treatment blocks vertical transmission.
• There is the possibility of reactivation in immunosuppressed patients, with severe consequences.
• Approximately 30% of persons with Chagas disease develop heart disease, with subsequent morbidity and mortality and added 
cost for the health system.
• Chagas disease carries a risk of stigmatisation. Better knowledge and normalisation of the disease improves the negative 
perception that often keeps patients from being diagnosed and treated early.
How substantial are the desirable anticipated effects? Large
How substantial are the undesirable anticipated effects? Moderate
Research evidence and remarks from the Panel
See Table 1 for a summary of findings for the outcomes of interest.
The prevalence of the disease in the study population, the rate of vertical transmission, and the rate of complications—mainly 
cardiovascular complications—justify screening. In the case of indication for treatment, treatment of chronic infection in 
children younger than 19 years is very useful, while in adults, it should be questioned owing to the lack of quality studies. The 
efficacy of treatment in chronic infection may be questionable, especially for patients with moderate to severe cardiopathy. The 
marginal effect of treatment for adults in this phase of the disease could be due to considerable differences between studies 
[51-55,68]. While the tolerability of parasiticidal treatment is good in children, it is important to highlight the poor tolerability 
of treatment in adults: up to 44% of patients treated with benznidazole experience adverse effects, which have an impact on 
discontinuation of treatment (11% of all treated patients) [56]. The adverse effects of screening are minimal, i.e. those associated 
with blood sampling and the potential psychological consequences of having the disease, which may lead to stigmatisation. 
Box 1.a
Evidence-to-decision framework for the formulation of recommendations for screening of migrants for Trypanosoma cruzi
CI: confidence interval; ECG: electrocardiogram; ICER: incremental cost-effectiveness ratio; LVEF: left ventricular ejection fraction; QALY: 
quality-adjusted life year.
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However, treatment with trypanocidal agents led to a high rate of adverse effects (on occasion up to 50%), some of which were 
severe. There is little evidence on the real cure rates in adult patients with chronic disease, which may be around 30% [68].
What is the overall certainty of the evidence of the effects? Low
Research evidence and remarks from the Panel
The studies evaluated for this question are observational (generally cross-sectional) with a prospective or retrospective design. 
The populations evaluated are heterogeneous. The quality of the results of these studies can be affected by selection bias. 
Furthermore, most of the combined analyses for the outcomes of interest revealed a very notable rate of statistical heterogeneity. 
However, this variability decreased when studies with well-defined populations (e.g. pregnant women) were evaluated together 
or when variability was attributed to estimations from few studies. Therefore, in most studies it was not considered a reason for 
reduced quality of evidence.
Is there major uncertainty about or variability in how much people value the main outcomes? There may be major uncertainty or 
variability.
Research evidence and remarks from the Panel
A study on Bolivian women with Chagas disease in Madrid revealed relevant aspects of their knowledge of and attitudes 
towards the disease. Most knew that the disease was transmitted by a vector, could be asymptomatic, and could lead to severe 
complications such as sudden death and heart failure. While there is some confusion over treatment, the women know that it is 
available [69].
The study included women from a country where Chagas disease was highly prevalent. There may be major differences between 
people from different countries.
Does the balance between desired and undesired effects favour the intervention or the comparison? The balance between desired 
and undesired effects favours the intervention.
Research evidence and remarks from the Panel
The expected benefit is centred on three basic aspects:
• Intervention prevents vertical transmission, with treatment offered after serology-based diagnosis in women of reproductive 
age from endemic areas. Furthermore, detection of the disease in a pregnant woman enables early diagnosis and treatment of the 
newborn, thus ensuring cure rates close to 100% during the first year, with very few adverse effects. Early diagnosis and treatment 
of the disease could prevent mainly cardiovascular complications, although evidence is scarce.
• The risks associated with treatment can be controlled to a large extent with appropriate follow-up at specialised clinics during 
the administration period.
• Screening of donors to prevent transmission through blood products and organs is addressed in current Spanish legislation 
(Royal Decree 1088/2005, dated 16 September 2005 (BOE-A-2005–15514))
Is the intervention acceptable to key stakeholders (population, professionals)? Probably
Research evidence and remarks from the Panel
The participants in the study on Bolivian women living in Madrid showed a certain degree of indifference and a lack of 
understanding of the risk of contracting the disease [69]. Participants who presented symptoms or had relatives with symptomatic 
disease expressed their concern for the more severe complications of the disease and the possibility of vertical transmission. In 
addition, fear of rejection by their social circle because of the disease was detected.
In a similar study in the US, participants also expressed their concern about the lack of knowledge of the disease by health 
professionals and about more logistic aspects, such as difficulties reaching health centres or having sufficient time to attend an 
appointment. Of note, the participants in this study were at risk of social exclusion [70].
Stigmatisation because of the disease in specific groups should be taken into consideration when screening. Education, 
knowledge of the disease and easy access to diagnosis and treatment are necessary in order to overcome this problem.
CI: confidence interval; ECG: electrocardiogram; ICER: incremental cost-effectiveness ratio; LVEF: left ventricular ejection fraction; QALY: 
quality-adjusted life year.
Box 1.b
Evidence-to-decision framework for the formulation of recommendations for screening of migrants for Trypanosoma cruzi
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respective 95% CI using the Freeman-Tukey double arc-
sine transformation [18]. All tests were two-tailed. We 
used the random effects model of DerSimonian and 
Laird to evaluate heterogeneity between studies based 
on an indicator of variation between studies attributed 
to heterogeneity rather than to chance (I2) [15]. We con-
structed forest plots showing the point prevalence and 
the 95% CI of the individual studies, as well as pooled 
estimates with the 95% CI, both for the total population 
and for subgroups of interest (e.g. participants’ origin, 
blood donors and pregnant women). The analyses were 
performed using the Metaprop command of Stata 12.0 
(Stata Statistical Software: Release 12. College Station: 
StataCorp LP).
The quality of evidence was classified as high, moder-
ate, low or very low in accordance with the methodo-
logical guidelines of the Grading of Recommendations, 
Assessment, Development and Evaluation (GRADE) 
working group [19]. The process for evaluating the 
Does the cost-effectiveness of the intervention favour the intervention or the comparison? 
They probably favour the intervention.
Research evidence and remarks from the Panel
An economic evaluation [11] evaluated the most efficient strategy for controlling Chagas disease among Latin American 
immigrants living in Spain. The study showed that not screening was more expensive and less effective and was dominated by 
other strategies from the societal perspective and from the perspective of the Spanish National Health System (SNHS). One of 
the most efficient strategies from both perspectives was screening of pregnant women, their newborns and first- and second-
degree relatives of disease-positive mothers. From the SNHS perspective, moving from the strategy of screening ‘mother 
and newborn’ to the strategy of including ‘relatives of a disease-positive mother’ would involve a mean increase of EUR 301 
per patient and QALY gained. In addition, moving from a strategy of ‘relatives of a disease-positive mother’ to ‘relatives of a 
disease-negative mother’ would involve a mean increase of EUR: 30,844 per patient and QALY gained.
The parameters whose modification had the greatest effect on the results were efficacy of treatment of chronic disease and 
disease prevalence. We observed that it could prove efficient to extend a programme of this type to relatives of disease-
negative mothers if the efficacy of treatment increased or the programme targeted the population at greatest risk.
Results were recently published for an economic evaluation of systematic screening for Chagas disease in the Latin American 
population receiving primary care in Europe [71]. The evaluation consisted of a decision-making approach based on a Markov 
model in which the impact of systematic screening (all asymptomatic Latin Americans seen at primary care setting, treatment 
and follow-up of positive cases) was compared with screening and treatment of symptomatic persons. The model was based 
on a simulation in a cohort of 100,000 Latin American citizens, with a T. cruzi infection rate of 4.2% (95% CI: 2.2–6.8) and a 
maximum of 5 years of treatment in positive cases. The results of the analysis according to the probabilistic models revealed a 
total cost of systematic screening of EUR 32,163,649 (95% CI: 31,263,705–33,063,593) compared with EUR 6,904,764 (95%: CI: 
6,703,258–7,106,270) for screening of symptomatic persons. The difference in QALY gained was 4,758.62 (95% CI: 4,618.42–
4,898.82) for systematic screening compared with testing only symptomatic patients, with an incremental cost (ICER) of EUR 
6,840.75 (95% CI: 6,255.75–7,425.75) for each QALY gained, treatment efficacy of 20% and EUR 4,243 for each QALY gained 
when efficacy was estimated to be 50%. Therefore, systematic screening in primary care would prove cost-effective, even in 
scenarios with a very low disease prevalence (0.05%).
Another economic evaluation compared a decision-making model for screening the newborn or the mother against the 
alternative of no screening [72]. All of the models revealed screening to be the dominant (clinically superior and cost saving) 
situation compared with not screening. The ICER for the screening in the newborn was EUR 22 per QALY gained compared with 
EUR 125 per QALY gained in the case of not screening. In the case of mothers, the ICER was EUR 96 per QALY gained compared 
with EUR 1,675 per QALY gained for not screening. Screening strategies were cost-effective, even in settings with a higher 
prevalence of Chagas disease (0.9%) and lower risk of vertical transmission (2.2%), where the ICER increased by only EUR 37.50 
per QALY gained for both strategies.
It would be necessary to perform studies on the costs for the health system of a patient with symptomatic Chagas disease, 
especially when this involved heart disease.
CI: confidence interval; ECG: electrocardiogram; ICER: incremental cost-effectiveness ratio; LVEF: left ventricular ejection fraction; QALY: 
quality-adjusted life year.
Box 1.c
Evidence-to-decision framework for the formulation of recommendations for screening of migrants for Trypanosoma cruzi
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quality of the evidence was included in the summary 
of findings Tables [20], which also included the main 
effect estimates for the outcomes of interest.
Evidence to decision framework
In order to formulate the recommendations in an 
explicit and reasoned manner, we used an evidence 
to decision (EtD) framework to inform the Panel of the 
most relevant aspects necessary for taking decisions 
and thus making them easy to justify [21].
In addition to the information from the literature review 
on the outcomes defined in the clinical question, we 
assessed economic evaluations and studies on percep-
tions and experiences of the population of interest in 
order to gather relevant information to inform recom-
mendations on use of resources, values and prefer-
ences and acceptability of screening.
Results
We summarise the main findings from the scientific lit-
erature review and the discussion of the Panel for for-
mulating the recommendations. A complete report can 
be consulted online (Supplement 2).
The search yielded 470 references. Based on the eligi-
bility criteria, we identified 65 references for which the 
complete text was reviewed. Of these, we selected 33 
studies that fulfilled the inclusion criteria [5-7,9,22-50]. 
A PRISMA flow diagram (Figure 1) details the eligibility 
process. 
More than half of the studies were prospective (n=20) 
with a cross-sectional design (n=8) and were carried 
out in Spain (n=23) and the rest of Europe (n=10). 
Almost half of the studies focussed on the general 
migrant population (n=16), while the remainder evalu-
ated vertical transmission (n=13) or included blood 
donors (n=6). Follow-up varied from a mean of 32 
months in prospective studies (range: 12–72 months) 
to 87 months in retrospective studies (range: 13–148 
months). The screening tests varied depending on the 
study, although they generally involved a combination 
of an ELISA-based approach and indirect immunofluo-
rescence; the studies also used other, confirmatory 
tests. The criterion for a positive screening result 
was generally consistent with the recommendations 
of the WHO, according to which a case of chronic  T. 
cruzi infection is defined by two positive results in dif-
ferent serology tests [12].
Impact of screening for Trypanosoma cruzi
Table 1 summarises the findings of the literature review 
for the outcomes of interest.
Patients with Trypanosoma cruzi infection
We collected data from 28 observational studies cover-
ing 1,441 cases in a population of 19,735 immigrants 
from endemic areas. The total pooled prevalence 
of T. cruzi  infection was 6.08% (95% CI: 3.24–9.69%; 
I2 = 98.82%). Of the total number of cases where it was 
possible to identify the country of origin (n = 986; from 
17 countries), 90% (n = 884) were from Bolivia, fol-
lowed by Argentina (n = 32; 3.3%), Paraguay (n = 25; 
2.5%) and Ecuador (n = 12; 1.22%). Prevalence was 
systematically higher in Bolivian immigrants than in all 
other groups. Considerable differences were found in 
Should immigrants and refugees be screened for T. cruzi infection?
1. Screening for Chagas disease is recommended in pregnant women (from endemic areas or daughters of women from these 
areas). Strong recommendation.
2. Screening for Chagas disease is recommended in women of reproductive age from endemic areas who wish to become 
pregnant and daughters of women from these areas. Strong recommendation.
3. Screening for Chagas disease is recommended in blood and organ donors (from endemic areas or children of mothers from 
these areas). Strong recommendation.
4. Screening for Chagas disease is suggested in immunosuppressed patients or those at risk of immunosuppression (persons 
from endemic areas or children of mothers from these areas), ideally before immunosuppression or at diagnosis of HIV 
infection. Conditional recommendation.
5. It has been suggested that asymptomatic adults from endemic areas should receive help in making a joint decision on 
the possibility of screening for Chagas disease. They should be informed about the characteristics and consequences of the 
disease, the advantages and disadvantages of treatment and the limited benefit of treatment in the case of a latent infection. 
Conditional recommendation.
HIV: human immunodeficiency virus.
Box 2
Recommendations on the screening of migrants for Trypanosoma cruzi
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population subgroups according to the setting where 
screening was performed (Table 1, Figure 2).
Vertical transmission of Trypanosoma 
cruzi infection
Vertical transmission was recorded in 27 cases from 13 
observational studies covering a total of 502 children 
born to mothers with chronic  T. cruzi  infection [6,35-
43,46,49,50]. The pooled transmission rate was three 
per 100 live births (95% CI: 1–6).
Organ involvement
We recorded 343 cases of mild to moderate cardiovas-
cular disease in 1,946 seropositive patients (nine stud-
ies), a cumulative prevalence of 19% (95% CI: 13–27%) 
[6,7,9,24,29,45-48]. Furthermore, nine studies yielded 
180 cases with a mild to moderate digestive tract disor-
der from 1,862 patients (pooled prevalence: 5%; 95% 
CI: 2–11%) [7,24,25,28,29,45-48].
Nine observational studies yielded a cumulative preva-
lence of severe cardiac events of 1% (95% CI: 0–2%; 39 
events in 1,946 patients) [6,7,9,24,29,45-48]. The esti-
mated cumulative prevalence of megasyndrome was 
lower (0%; 95% CI: 0–1%; 45 events in 1,935 patients) 
[6,7,9,24,25,28,29,45-48].
Indication for treatment
Data from 11 observational studies showed that in 81% 
of detected cases, treatment was started with a trypan-
ocidal drug (95% CI 67–93%) [6,29,30,35,37,39,43,45-
48]. These studies revealed treatment-related adverse 
effects in 47% of cases (95% CI: 32–63%).
The usefulness of trypanocidal treatment in adults with 
Chagas disease is questionable. A 2009 meta-analysis 
showed limited benefit of treatment with benznidazole 
in chronic disease, with a marginal effect compared with 
placebo [51]. The only randomised clinical trial compar-
ing benznidazole with placebo revealed no benefit of 
benznidazole in clinical outcomes (heart disease or 
death); it reported that T. cruzi remained undetectable 
in PCR in more patients treated with benznidazole than 
in those who received placebo, although no associa-
tion with clinical outcomes was observed [52]. Since 
the study patients had moderate to severe heart dis-
ease, we do not know whether benznidazole controls 
disease in patients with mild or no organ involvement. 
Furthermore, recent clinical trials on the use of imida-
zoles (posaconazole or ravuconazole) alone [53,54] or 
in combination with benznidazole [55] showed these 
to be less efficacious than benznidazole based on 
microbiological response markers (PCR for  T. cruzi). A 
systematic review on safety of treatment showed that 
benznidazole was poorly tolerated, with a frequency of 
adverse effects of 44% and discontinuation of treat-
ment in 11% of patients [56].
Nevertheless, promising alternative regimens based 
on different doses and durations of treatment with 
benznidazole are being developed. The objective of 
trials investigating these regimens is to improve toler-
ability while maintaining treatment efficacy (Multibenz 
NCT03191162; BENDITA NCT03378661; BETTY 
NCT03672487). Preliminary results have demonstrated 
reductions in the frequency of adverse events, with 
equivalent percentages of undetectable T. cruzi  in PCR 
at 12 months [57].
Mortality
Two studies reported one case each of sudden death 
from cardiac causes secondary to Chagas disease [6,7].
Quality of evidence
The Panel rated the overall quality of evidence for the 
evaluated outcomes as low. Given the absence of clini-
cal trials that evaluated the efficacy of screening in the 
population of interest, the included studies were obser-
vational (generally cross-sectional), with a prospective 
or retrospective design and, therefore, a risk of selec-
tion bias that could affect confidence in the reported 
results. The study populations were heterogeneous, 
resulting in marked statistical heterogeneity for the 
outcomes of interest in most analyses. However, this 
variability diminished when studies with well-defined 
populations (e.g. pregnant women) were evaluated 
together as a subgroup (Figure 2).
Recommendations
Box 1 shows an adaptation of the EtD framework based 
on which the Panel discussed and formulated the rec-
ommendations. The complete EtD framework can be 
consulted in  Supplement 2. The Panel subsequently 
formulated the recommendations included in Box 2.
Justification
Recommendations have been formulated in favour 
of screening owing to the high prevalence of  T. 
cruzi  infection among immigrants from Latin America, 
especially Bolivia. Furthermore, the possibility 
of autochthonous transmission, mainly vertical 
transmission, is notable in Spain. Given that the 
response to trypanocidal treatment is greater than 
90% during the first year of life, early detection in the 
children of affected mothers provides huge benefits. 
A strong recommendation has been formulated for 
women of reproductive age who wish to become preg-
nant, since this situation is considered to be an oppor-
tunity for preventing transmission to future children, 
taking into account the rate of maternofetal transmis-
sion of Chagas disease (3–7%) [2,13]. Transmission is 
more frequent when PCR in blood is positive than when 
it is negative.
The Panel also considered that blood or organ dona-
tion is a situation where identification of people with 
infection could be particularly relevant for preventing 
transmission and providing appropriate treatment for 
positive cases.
Immunosuppressed patients are at risk of reactivation 
of disease and progressing to a more severe clinical 
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condition; therefore, the potential benefit of treat-
ment is greater in this subgroup of patients. Ideally, 
screening should be performed before immunosup-
pression is detected, although it is not always possi-
ble to know this in advance. Therefore, screening can 
also be performed once immunosuppression has been 
confirmed. However, in the case of patients from non-
endemic countries, it is not recommended to repeat 
serology when the result is negative. The following 
patient groups are considered as immunosuppressed: 
patients taking immunosuppressants (e.g., cytostatic 
agents, corticosteroids) at doses > 1 mg/kg for more 
than 1 month, biological drugs with potent immunosup-
pressive action or other types of immunosuppressive 
antineoplastic chemotherapy, transplant recipients, 
HIV-infected patients and patients with haematological 
cancer.
In the case of asymptomatic adults, a conditional 
recommendation was formulated on shared decision 
making with the patient, given the beneficial effect of 
treatment and the low quality of evidence in this patient 
group. However, the Panel considered the option of 
screening involving the patient in diagnosis and treat-
ment for several reasons: (i) poor visibility and knowl-
edge of the disease, (ii) the major psychological impact 
of the disease on the potentially affected population 
and (iii) the fact that the benefit of treatment in this 
group of patients would be strictly on an individual 
basis. In non-endemic countries, patients are screened 
only once since there is no risk unless they return to 
an endemic country for long periods. Therefore, a 
pregnant woman with a negative result for  T. cruzi  in 
serology testing does not require further screening in 
subsequent pregnancies if she remains in Spain.
Discussion 
The Panel of the SEIMC reviewed the literature to 
determine the appropriateness of screening for  T. 
cruzi  infection in immigrants and refugees and used 
explicit criteria to formulate a series of reasoned 
recommendations for this purpose. Following this 
rigorous and systematic methodology, we identified 
five situations where screening for  T. cruzi  infection 
is indicated. The recommendations are justified by 
the high prevalence of this problem in immigrants 
from Latin America and a notable rate of autochtho-
nous transmission in Spain, mainly owing to vertical 
transmission.
Trypanosoma cruzi  infection is the most common 
imported parasitic disease in Spain. Nevertheless, 
there remains much room for improvement with 
respect to diagnosis. A Royal Decree from 2005 set out 
the minimum conditions and technical requirements 
for blood donation (RD 1088/2005). This law covered 
screening for T. cruzi  infection. Similarly, screening for 
the infection has been part of transplant programmes 
for several years. However, it is not yet part of routine 
practice in protocols for pregnant women in most 
Autonomous Communities, despite the fact that 
recommendations are in place [58,59]. Likewise, most 
countries in the European Union do not have legisla-
tion regulating screening for Chagas disease in preg-
nant women from endemic areas [60]. Furthermore, 
the prevalence of  T. cruzi  infection is clearly higher in 
populations that may also be infected by HIV, hepa-
titis B virus and syphilis and that do in fact undergo 
regular screening [61,62]. This disease burden has 
been observed in studies on the seroprevalence of  T. 
cruzi and on the serological profile of pregnant women, 
with a prevalence of 1.75–5% [42,63,64]. The results of 
our review show a pooled vertical transmission rate of 
three per 100 live births, which is lower than reported 
in another systematic review (4.7 per 100 live births) 
[65]. Similarly, screening should be included in health 
programmes aimed at immigrant children or children of 
immigrants from endemic areas [11,42].
The Panel used a systematic and explicit methodol-
ogy to formulate the recommendations. While we were 
unable to identify a clinical trial that could provide data 
on the relevance of screening for T. cruzi  infection, we 
evaluated a large number of studies from which we were 
able to retrieve data on the outcomes of interest based 
on the experience of other authors. Using data from the 
literature review, the Panel created an EtD framework 
that enabled an explicit and reasoned assessment of 
the main criteria for formulating recommendations [21]. 
When it comes to implementing the recommendations, 
this process makes it possible for users to evaluate all 
the aspects and opinions that the Panel took into con-
sideration during the formulation process.
The paucity of relevant literature and its limited quality 
with respect to the decision-making process in some 
cases (e.g. asymptomatic adults) could limit the pro-
posal for recommendations in these specific situations 
or open a debate on their relevance. In any case, the 
process for using the available information and justi-
fying the different opinions of the Panel validates the 
recommendations, since these explicitly reflect all the 
considerations taken into account, even those that 
were more subjective.
Another potential limitation of this study is that we 
did not include studies conducted explicitly in chil-
dren younger than 14 years. Most of the studies in 
non-endemic countries are performed in migrants 
and refugees older than 14 years (younger people are 
rarely included because of difficulties with informed 
consent). Nevertheless, and given that Chagas dis-
ease can be transmitted vertically, studies including 
screening of neonates and of minors born to mothers 
at risk of vertical transmission, were also taken into 
consideration.
While Latin American immigrants in Spain account 
for 24.9% of all foreigners (Bolivians for 1.9%) and 
the greatest increases in non-EU foreign nationals in 
2018 were recorded among citizens of endemic coun-
tries such as Venezuela and Colombia [66], there are 
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no protocols for screening for T. cruzi infection in most 
Spanish Autonomous Communities. Despite agreement 
in Europe on the need for screening to control 
transmission in blood banks and in the transplantation 
setting, there is considerable uncertainty with regard 
to congenital transmission and the provision of care 
to Latin American immigrants. In fact, this uncertainty 
is so widespread that other similar guidelines (e.g. 
guidelines from the European Centre for Disease 
Prevention and Control on screening and vaccination 
for infectious diseases in newly arrived migrants within 
the European Union and European Economic Area) have 
not addressed this issue [67].
The recommendations made by the SEIMC can serve 
as a guide for the development of protocols and help 
health professionals make decisions on screening for 
this disease in clinical practice in other countries.
Conclusions
The use of a rigorous methodology enabled us to for-
mulate recommendations in an explicit and reasoned 
way by ensuring that during the formulation process, 
the Panel had information on the most important crite-
ria for decision making.
As for the usefulness of screening immigrants and refu-
gees for  T. cruzi, the Panel of the SEIMC identified a 
series of situations in which screening would be indi-
cated. The recommendation is aimed at people who 
could benefit most from the diagnosis (children and 
adolescents up to 19 years of age, young women of 
reproductive age and pregnant women), mainly owing 
to the high prevalence of this infection in immigrants 
(especially Bolivians) and the possibility of preventing 
autochthonous transmission.
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